Completing data — refresh the page later to see the latest
128954-45-0COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1BPZSYCZIITTYBL-UHFFFAOYSA-NN-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide is a phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent. It is a member of formamides, a member of phenylethanolamines, a member of phenols, a secondary alcohol and a secondary amino compound.
log Kow = 1.40 /Estimated/
2.2
Slightly (as fumarate salt)
In water, 1.12X10+4 mg/L at 25 °C /Estimated/
4.16e-02 g/L
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Danger
H332 (28.6%): Harmful if inhaled [Warning Acute toxicity, inhalation]
P203, P260, P261, P263, P264, P270, P271, P273, P280, P304+P340, P308+P316, P317, P318, P319, P321, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 14 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
H332 (100%): Harmful if inhaled [Warning Acute toxicity, inhalation]
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl formoterol fumarate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Formoterol Fumarate/
Acute Tox. 4 (28.6%)
Acute Tox. 4 (100%)
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.
R - Respiratory system
R - Respiratory system
QR - Respiratory system
QR - Respiratory system
Formoterol works locally in the lungs as a bronchodilator, relaxing smooth muscle and opening up the airways. It possesses both a rapid onset of action (approximately 2-3 minutes) and a long duration of action (up to 12 hours). The use of long-acting beta-agonists (LABAs), such as formoterol, without concomitant inhaled corticosteroids in asthmatic patients should be avoided, as LABA monotherapy has been associated with an increased risk of asthma-related death.
Formoterol is a relatively selective long-acting agonist of beta<sub>2</sub>-adrenergic receptors, although it does carry some degree of activity at beta<sub>1</sub> and beta<sub>3</sub> receptors. Beta<sub>2</sub> receptors are found predominantly in bronchial smooth muscle (with a relatively minor amount found in cardiac tissue) whereas beta<sub>1</sub> receptors are the predominant adrenergic receptors found in the heart - for this reason, selectivity for beta<sub>2</sub> receptors is desirable in the treatment of pulmonary diseases such as COPD and asthma. Formoterol has demonstrated an approximately 200-fold greater activity at beta<sub>2</sub> receptors over beta<sub>1</sub> receptors. On a molecular level, activation of beta receptors by agonists like formoterol stimulates intracellular adenylyl cyclase, an enzyme responsible for the conversion of ATP to cyclic AMP (cAMP). The increased levels of cAMP in bronchial smooth muscle tissue result in relaxation of these muscles and subsequent dilation of the airways, as well as inhibition of the release of hypersensitivity mediators (e.g. histamine, leukotrienes) from culprit cells, especially mast cells.
Formoterol is a long-acting selective stimulator of the beta2-adrenergic receptors in bronchial smooth muscle. This stimulation causes relaxation of smooth muscle fibers and produces bronchodilation.
128954-45-0、73573-87-2DTXSID20860603CHEMBL1256786CHEBI:63082White to yellowish crystalline powder which is freely soluble in glacial acetic acid, soluble in methanol, sparingly soluble in ethanol and isopropanol, slightly soluble in water, and practically insoluble in acetone, ethyl acetate, and diethyl ether. /Fumurate/
Hydroxyl radical reaction rate constant = 2.0X10-14 cu cm/molc-sec at 25 °C /Estimated/
Concomitant treatment /with monoamine oxidase inhibitors, including furazolidine and procarbazine/ may prolong the QTc interval and increase the risk of ventricular arrhythmias; may increase chance of hypertensive reactions.
May increase risk of arrhythmias in patients receiving halogenated hydrocarbon anesthesia.
Concomitant treatment /with tricyclic antidepressants, disopyramide, phenothiazines, procainamide or quinidine/may prolong the QTc interval and increase the risk of ventricular arrhythmias.
/Alcohol, levodopa, levothyroxine, oxytocin/ may impair cardiac tolerance towards beta2-sympathomimetics.
For more Interactions (Complete) data for FORMOTEROL (6 total), please visit the HSDB record page.
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 430(SRC), determined from a structure estimation method(2), indicates that formoterol is expected to have moderate mobility in soil(SRC). Volatilization of formoterol from moist soil surfaces is not expected to be an important fate process(SRC) given the natural cationic state of the compound and an estimated Henry's Law constant of 9.0X10-23 atm-cu m/mole(SRC), using a fragment constant estimation method(3). The pKa1 (amine) and pKa2 (phenol) of formoterol are 7.9 and 9.2(5), respectively, indicating that this compound will exist primarily in the protonated form below pH 7 and in its zwitterion form in the pH range of 7 to 9. Cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(6). Formoterol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.0X10-14 mm Hg(SRC), determined from a fragment constant method(4). Biodegradation data for soil were not available(SRC, 2004).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 430(SRC), determined from a structure estimation method(2), indicates that formoterol is not expected to adsorb to suspended solids and sediment(SRC). However, the pKa1 (amine) and pKa2 (phenol) of formoterol are 7.9 and 9.2(7), respectively, indicating that this compound will exist primarily in the protonated form below pH 7 and in its zwitterion form in the pH range of 7 to 9. Cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(5). Volatilization from water surfaces is not expected(3) given the natural cationic state of the compound and based upon an estimated Henry's Law constant of 9.0X10-23 atm-cu m/mole(SRC), developed using a fragment constant estimation method(4). According to a classification scheme(6), an estimated BCF of 0.5(SRC), from an estimated log Kow of 1.4(8) and a regression-derived equation(9), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data for water were not available(SRC, 2004).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), formoterol, which has an estimated vapor pressure of 5.0X10-14 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase formoterol may be removed from the air by wet and dry deposition(SRC).
Using a structure estimation method based on molecular connectivity indices(1), the Koc for formoterol can be estimated to be 430(SRC). According to a classification scheme(2), this estimated Koc value suggests that formoterol is expected to have moderate mobility in soil. The pKa1 (amine) and pKa2 (phenol) of formoterol are 7.9 and 9.2(3), respectively, indicating that this compound will exist primarily in the protonated form below pH 7 and in its zwitterion form in the pH range of 7 to 9(4). Cations generally adsorb more strongly to organic carbon and clay than their neutral counterparts(4).
/SIGNS AND SYMPTOMS/ As with other inhaled beta2-receptor agonists, a patient may develop acute bronchospasm, which may be life-threatening, immediately upon inhalation of formoterol. If paradoxical bronchospasm occurs, formoterol should be discontinued immediately and alternative therapy instituted.
/SIGNS AND SYMPTOMS/ The expected signs and symptoms with overdosage of foradil aerolizer are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms ... e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 beats/min., arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, and insomnia. Metabolic acidosis may also occur. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of Foradil aerolizer.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Formoterol
DILI Negative
Respiratory (inhalation)
DOI:10.1016/j.drudis.2019.09.022
An estimated BCF of 0.5 was calculated for formoterol(SRC), using an estimated log Kow of 1.4(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).
The Henry's Law constant for formoterol is estimated as 9.0X10-23 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that formoterol is expected to be essentially nonvolatile from water surfaces(2). Formoterol is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 5.0X10-14 mm Hg(SRC), determined from a fragment constant method(3).
/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In animal studies formoterol has been shown to cause stillbirth and neonatal mortality at oral doses of 6 mg/kg (approximately 2000 times the maximum recommended daily inhalation dose in humans on a mg/sq m basis) and above in rats receiving the drug during the late stage of pregnancy. When formoterol was given to rats throughout organogenesis, oral doses of 0.2 mg/kg and above delayed ossification of the fetus, and doses of 6 mg/kg and above decreased fetal weight.
/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Reproduction studies in rats revealed no impairment of fertility at oral doses up to 3 mg/kg.
/GENOTOXICITY/ Formoterol was not shown to be mutagenic or clastogenic in any of the following: bacterial and mammalian cell mutagenicity tests, chromosome analyses tests in mammalian cells, unscheduled DNA synthesis repair test in human fibroblasts or in rat hepatocytes, transformation assay in mammalian fibroblasts and micronucleus tests in mice and in rats.
/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Carcinogenic potential of formoterol has been evaluated in drinking water and dietary studies in both rats and mice. The incidence of ovarian leiomyomas in rats was increased at doses of 15 mg/kg and above in the drinking water study and at 20 mg/kg in the dietary study. The incidence of benign ovarian theca-cell tumors in rats was increased at doses of 0.5 mg/kg and above in the dietary study. The incidence of adrenal subcapsular adenomas and carcinomas was increased in male mice at doses of 69 mg/kg and above in the drinking water study, but not at doses up to 50 mg/kg in the dietary study. The incidence of hepatocarcinomas was increased in the dietary study at doses of 20 and 50 mg/kg in female mice and 50 mg/kg in male mice. Uterine leiomyomas and leiomyosarcomas have been found in mice following oral administration of formoterol. Similarly, mesovarian leiomyomas have been found in rats following inhalation of formoterol.
For more Non-Human Toxicity Excerpts (Complete) data for FORMOTEROL (6 total), please visit the HSDB record page.
According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), formoterol, which has an estimated vapor pressure of 5.0X10-14 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase and atmospheric reaction with hydroxyl radicals or ozone is not expected. Formoterol is not expected to undergo hydrolysis in the environment due to the lack of hydrolyzable functional groups(3) nor to directly photolyze due to the lack of absorption in the environmental UV spectrum (>290 nm).
Occupational exposure to formoterol may occur through inhalation and dermal contact with this compound at workplaces where formoterol is produced or used. The general population may be exposed to formoterol via ingestion of pharmaceutical products containing formoterol. (SRC)
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl formoterol fumarate, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Formoterol Fumarate/
Formoterol stimulates beta2-adrenergic receptors and apparently has little or no effect on beta1- or alpha-adrenergic receptors. The drug's beta-adrenergic effects appear to result from stimulation of the production of cyclic adeno-3'-5'-monophosphate (cAMP)by activation of adenyl cyclase. Cyclic AMP mediate numerous cellular responses, increased concentrations of cAMP are associated with relaxation of bronchial smooth muscle and suppression of some aspects of inflammation, such as inhibition of release proinflammatory mast cell mediators(eg histamine, leukotrienes).
The average terminal elimination half-life of formoterol following inhalation is 7-10 hours, depending on the formulation given. The plasma half-life of formoterol has been estimated to be 3.4 hours following oral administration and 1.7-2.3 hours following inhalation.
Mean terminal: 10 hours
Formoterol is metabolized primarily via direct glucuronidation of the parent drug and via O-demethylation of the parent drug followed by glucuronidation. Minor pathways include sulfate conjugation of the parent drug and deformylation of the parent drug followed by sulfate conjugation, though these minor pathways have not been fully characterized. The major pathway of formoterol metabolism is a direct glucuronidation of the parent drug at its phenolic hydroxyl group, while the second most prominent pathway involves O-demethylation following by glucuronidation at the phenolic hydroxyl group. _In vitro_ studies of formoterol disposition indicate that O-demethylation of formoterol involves a number of cytochrome P450 isoenzymes (CYP2D6, CYP2C19, CYP2C9, and CYP2A6) and glucuronidation involves a number of UDP-glucuronosyltransferase isoenzymes (UGT1A1, UGT1A8, UGT1A9, UGT2B7, and UGT2B15), though specific roles for individual enzymes have not been elucidated.
Formoterol is metabolized primarily by direct glucuronidation at either the phenolic or aliphatic hydroxyl group and O-demethylation followed by glucuronide conjugation at either phenolic hydroxyl groups. Minor pathways involve sulfate conjugation of formoterol and deformylation followed by sulfate conjugation. The most prominent pathway involves direct conjugation at the phenolic hydroxyl group. The second major pathway involves O-demethylation followed by conjugation at the phenolic 2'-hydroxyl group. Four cytochrome P450 isozymes (CYP2D6, CYP2C19, CYP2C9 and CYP2A6) are involved in the O-demethylation of formoterol. Formoterol did not inhibit CYP450 enzymes at therapeutically relevant concentrations. Some patients may be deficient in CYP2D6 or 2C19 or both. Whether a deficiency in one or both of these isozymes results in elevated systemic exposure to formoterol or systemic adverse effects has not been adequately explored.
Formoterol was conjugated to inactive glucuronides and a previously unidentified sulfate. The phenol glucuronide of formoterol was the main metabolite in urine. Formoterol was also O-demethylated and deformylated. Plasma exposure to these pharmacologically active metabolites was low. O-demethylated formoterol was seen mainly as inactive glucuronide conjugates and deformylated formoterol only as an inactive sulfate conjugate. Intact formoterol and O-demethylated formoterol dominated recovery in feces. Mean recovery of unidentified metabolites was 7. 0% in urine and 2.0% in feces.
5ZZ84GCW8B
FORMOTEROL
Mechanisms of Action [MoA] - Adrenergic beta2-Agonists
Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist
Formoterol is a beta2-Adrenergic Agonist. The mechanism of action of formoterol is as an Adrenergic beta2-Agonist.
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
The pulmonary bioavailability of formoterol has been estimated to be about 43% of the delivered dose, while the total systemic bioavailability is approximately 60% of the delivered dose (as systemic bioavailability accounts for absorption in the gut). Formoterol is rapidly absorbed into plasma following inhalation. In healthy adults, formoterol Tmax ranged from 0.167 to 0.5 hours. Following a single dose of 10 mcg, Cmax and AUC were 22 pmol/L and 81 pmol.h/L, respectively. In asthmatic adult patients, Tmax ranged from 0.58 to 1.97 hours. Following single-dose administration of 10mcg, Cmax and AUC0-12h were 22 pmol/L and 125 pmol.h/L, respectively; following multiple-dose administration of 10 mcg, Cmax and AUC0-12h were 41 pmol/L and 226 pmol.h/L, respectively. Absorption appears to be proportional to dose across standard dosing ranges.
Elimination differs depending on the route and formulation administered. Following oral administration in 2 healthy subjects, approximately 59-62% and 32-34% of an administered dose was eliminated in the urine and feces, respectively. Another study which attempted to mimic inhalation via combined intravenous/oral administration noted approximately 62% of the administered dose in the urine and 24% in the feces. Following inhalation in patients with asthma, approximately 10% and 15-18% of the administered dose was excreted in urine as unchanged parent drug and direct formoterol glucuronides, respectively, and corresponding values in patients with COPD were 7% and 6-9%, respectively.
Renal clearance of formoterol following inhalation is approximately 157 mL/min.
Protein binding: Moderate 61-64%. Serum albumin binding was 31% to 38% over a range of 5 to 500 ng/mL.
Bioavailability: Pulmonary: 21-37%; Total systemic: 46%.
It is not known whether formoterol is distributed in human breast milk. However, it is distributed in rat milk after oral administration.
Preparation: M. Murakami et al, DE 2305092; eidem, US 3994974 (1973, 1976 both to Yamanouchi)
Information available in 2004 indicated that Formoterol was used in the manufacture of pharmaceutical preparations in the following countries: Austria, Belgium, Denmark, Greece, Ireland
Information available in 2004 indicated that Formoterol fumerate was used in the manufacture of pharmaceutical preparations in the following countries: Antigua & Barbuda, Argentina, Aruba, Australia, Austria, Bahamas, Barbados, Belgium, Belize, Bermuda, Brazil, Bulgaria, Canada, Cayman Islands, Chile, Colombia, Costa Rica, Czech Republic, Denmark, Dominican Republic, El Salvador, Ethiopia, Finland, France, Germany, Ghana, Greece, Grenada, Guatemala, Guyana, Haiti, Honduras, Hong Kong, Hungary, India, Indonesia, Ireland, Israel, Italy, Jamaica, Japan, Kenya, Libyan Arab Jamahiriya, Malawi, Malaysia, Malta, Mauritius, Mexico, Mozambique, Netherlands Antilles, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Panama, Poland, Portugal, Romania, Russian Federation, Saint Lucia, Saint Vincent & The Grenadines, Singapore, South Africa, Spain, Sudan, Suriname, Sweden, Switzerland, Thailand, Trinidad & Tobago, Turkey, Uganda, United Kingdom, United Republic of Tanzania, USA, Zambia, Zimbabwe (1,2) [NOTE: Information available in 2004 indicated that Formoterol fumerate was used in the manufacture of pharmaceutical preparations in the following countries: Argentina-DI, Spain-DI (2)] /Formoterol fumerate/
Information available in 2004 indicated that Formoterol hemifumerate was used in the manufacture of pharmaceutical preparations in the following countries: Austria, Brazil, Portugal, Singapore, Spain /Formoterol hemifumerate/
UsesFormoterol is a selective β2-adrenergic receptor agonist. Formoterol is used as an antiasthmatic.
DefinitionChEBI: N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide is a phenylethanoloamine having 4-hydroxy and 3-formamido substituents on the phenyl ring and an N-(4-methoxyphenyl)propan-2-yl substituent. It is a member of phenols, a member of formamides, a secondary amino compound, a secondary alcohol and a member of phenylethanolamines.